XML 68 R57.htm IDEA: XBRL DOCUMENT
v3.19.2

Collaborations and Licensing Arrangements - Additional Information (Detail) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 29, 2019 | Dec. 30, 2016 | May 31, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | Oct. 31, 2018 | Sep. 30, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue recognized from collaborations and services |  |  |  | $ 15,002,000 | $ 3,893,000 | $ 32,450,000 | $ 7,358,000 |  |  |
Deferred revenue - current |  |  |  | 32,370,000 |  | 32,370,000 |  | $ 36,885,000 |  |
Deferred revenue - long term |  |  |  | 8,399,000 |  | 8,399,000 |  | 10,680,000 |  |
Collaboration and License Agreement | Receptor |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | 400,000 |  | 400,000 |  |  |  |
Deferred revenue - current |  |  |  | 300,000 |  | 300,000 |  |  |  |
Proceeds from signing fees and upfront license fees |  | $ 1,300,000 |  |  |  |  |  |  |  |
Collaboration and License Agreement | United Therapeutics Corporation |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  | $ 45,000,000 |
Milestone Payment Received | $ 12,500,000 |  |  |  |  |  |  |  |  |
Revenue recognized from collaborations and services |  |  |  | 7,800,000 |  | 15,400,000 |  |  |  |
Deferred revenue |  |  |  | 40,800,000 |  | 40,800,000 |  |  |  |
Deferred revenue - current |  |  |  | 32,400,000 |  | 32,400,000 |  |  |  |
Deferred revenue - long term |  |  |  | 8,400,000 |  | 8,400,000 |  |  |  |
Total transaction price |  |  |  | 100,400,000 |  | 100,400,000 |  |  |  |
Collaboration and License Agreement | United Therapeutics Corporation | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Potential milestone payments to be receive |  |  |  | 37,500,000 |  | 37,500,000 |  |  |  |
Additional option exercise and development milestone payments to be receive |  |  |  | 40,000,000 |  | 40,000,000 |  |  |  |
Research Agreement | United Therapeutics Corporation |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  | $ 10,000,000
Revenue recognized from collaborations and services |  |  |  | 1,100,000 |  | 5,700,000 |  |  |  |
Deferred revenue |  |  |  | 500,000 |  | 500,000 |  |  |  |
Total transaction price |  |  |  | 10,000,000 |  | 10,000,000 |  |  |  |
Research Agreement | United Therapeutics Corporation | Product Prototype |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Total transaction price |  |  |  | 9,000,000 |  | $ 9,000,000 |  |  |  |
Revenue performance obligation, method used |  |  |  |  |  | The revenue for the product prototype is recognized using an output method (based on project milestones achieved and surveys of performance completed to date). The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation. |  |  |  |
Research Agreement | United Therapeutics Corporation | Engineering Consulting Services |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Total transaction price |  |  |  | 1,000,000 |  | $ 1,000,000 |  |  |  |
Revenue performance obligation, method used |  |  |  |  |  | The revenue for the engineering consulting services is recognized using a ratable method until the obligation is satisfied and the Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation. |  |  |  |
Research Agreement | United Therapeutics Corporation | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Potential milestone payments to be receive |  |  |  | 30,000,000 |  | $ 30,000,000 |  |  |  |
License and Distribution Agreement | Foreign Country | India Tax Authority |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Income Taxes Paid |  |  |  |  |  |  |  | $ 200,000 |  |
License and Distribution Agreement | Cipla Ltd |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | 2,000,000 |  | 2,000,000 |  |  |  |
Deferred revenue - current |  |  |  | $ 100,000 |  | $ 100,000 |  |  |  |
Marketing and distribution agreement date |  |  | 2018-05 |  |  |  |  |  |  |

X
- Definition Additional option exercise and development milestone payments to be received. + References No definition available. + Details
Name: | mnkd_AdditionalOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Date of agreement initiation for marketing and distribution. + References No definition available. + Details
Name: | mnkd_DateOfAgreementInitiationForMarketingAndDistribution
Namespace Prefix: | mnkd_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment received. + References No definition available. + Details
Name: | mnkd_MilestonePaymentReceived
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential milestone payments to be received. + References No definition available. + Details
Name: | mnkd_PotentialMilestonePaymentsToBeReceived
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Proceeds from signing fees and upfront license fees. + References No definition available. + Details
Name: | mnkd_ProceedsFromSigningFeesAndUpfrontLicenseFees
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | mnkd_UpfrontPaymentReceived
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585 + Details
Name: | us-gaap_IncomeTaxesPaid
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of method used to recognize revenue for performance obligation that is satisfied over time. Includes, but not is limited to, output or input method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130563-203045 + Details
Name: | us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mnkd_ReceptorLifeScienceIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnkd_ResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_ProductPrototypeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_EngineeringConsultingServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnkd_LicenseAndDistributionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_MinistryOfFinanceIndiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mnkd_CiplaLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |